CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE

Rhea-AI Summary

CanaQuest Medical Corp (OTC Markets: CANQF) announces a partnership with the Canadian Cannabis Dispute Resolution Centre (CCDRC). This collaboration aims to enhance understanding of medicinal cannabis and its applications in mental health management, focusing on scientifically backed evidence and research led by Dr. Steven Laviolette. The partnership will assist in developing training programs to mitigate cannabis-related conflicts in various sectors. CanaQuest's commitment includes promoting education on cannabinoid therapies for conditions like anxiety and PTSD.

Positive

• Partnership with CCDRC enhances educational outreach on medicinal cannabis.
• Focus on scientifically supported cannabinoid applications in mental health.
• Collaboration with a respected research team led by Dr. Steven Laviolette.

Negative

• None.

TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute Resolution Centre ("CCDRC"), a national organization that has developed cannabis-related education and training programs, both domestically and internationally, to assist different levels of government, the private sector, industry-specific organizations and associations.

The CCDRC/CanaQuest partnership will serve to raise global awareness. The common theme of all education relates to conflict resolution, which can be mitigated through education. A critical component of the partnership will be its focus on promoting scientifically backed evidence, pre-clinical data and published research papers of Dr. Steven Laviolette and his 13-person team at Western University in Canada.

 For the past 20 years, Dr. Laviolette and team have studied the effects of cannabinoids on mental health and wellness. Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia and Post Traumatic Stress Disorder (PTSD).

Treena Reilkoff, a Trauma Informed Mediator and Facilitator with the CCDRC stated, “We are pleased to have the opportunity to collaborate with CanaQuest. Our common goal is the recognition that medicinal cannabis is an alternative treatment to traditional pharmaceuticals and through education about the practicality and safety of medicinal cannabis, barriers and stigmas are reduced. The CCDRC is pleased to provide education and consulting services to help prevent cannabis-related workplace conflicts from escalating.” 

Paul Ramsay, CanaQuest Co-founder and President, added, “Our joint recognition of the importance of education and of people being able to have self-determination in their choices of prescriptions are the key drivers of this partnership.“

About CanaQuest Medical Corp:

CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, who has 20 years of research experience in the field of mental health and cannabinoids and oversees a team of 13 scientists at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine^®Rx and Mentabinol^®Rx in Canada and the USA.

As well, CanaQuest will be selling both products through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging, have been selected for production and distribution. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council.

For a short video on the research, visit https://www.youtube.com/watch?v=O_D4wkHHbDg
For more information on CanaQuest, visit http://www.canaquest.com

About Canadian Cannabis Dispute Resolution Centre:

The Canadian Cannabis Dispute Resolution Centre is a national organization of Canadian alternative dispute resolution specialists and conflict resolution trainers with expertise in cannabis law, policy and dispute resolution. The CCDRC aspires to be an innovator in identifying practical and pre-emptive solutions to cannabis-related disputes. Its members and training partners have developed training programs that focus on conflict resolution in the cannabis field, which has included the mediation of cannabis related disputes in the areas of workplace, multi-residential structures and law enforcement. The CCDRC has also provided guidance to local and regional governments on the development of dispute resolution mechanisms and by-law creation that concerns the use and growth of cannabis in the community. This knowledge and experience will assist organizations who encounter challenges of managing and defusing internal cannabis-related conflicts that may arise from its personnel’s use of recreational cannabis, edibles, extracts and topicals and the growing presence of medicinally prescribed cannabis.

For more information on Canadian Cannabis Dispute Resolution Centre, visit
https://www.cannabisdispute.ca/about-us

FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual Disclosure Statement filed with the OTC Markets for the most recent fiscal year.

CANAQUEST CONTACT:
Paul Ramsay, Co-Founder & President
CanaQuest Medical Corp
paul@canaquest.com:
Tel.: 416-704-3040 

CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE CONTACT:
Treena Reilkoff, Trauma Informed Mediator and Facilitator
treena@cannabisdispute.ca
Tel.: 416-854-1932

FAQ

What is the partnership between CanaQuest Medical Corp and CCDRC?

CanaQuest Medical Corp has partnered with the Canadian Cannabis Dispute Resolution Centre to promote education on medicinal cannabis and its mental health applications.

How does the CCDRC partnership benefit patients and investors of CANQF?

The partnership aims to raise awareness of cannabinoid therapies for mental health, potentially increasing demand for CanaQuest's products, benefiting both patients and investors.

What research is being promoted by CanaQuest in its partnership with CCDRC?

CanaQuest is promoting research on cannabinoid effects on mental health, including studies by Dr. Steven Laviolette on anxiety, depression, and PTSD.

What are the expected outcomes of the education programs from the CCDRC partnership?

The education programs are designed to mitigate cannabis-related conflicts and promote understanding of its safety and efficacy as a treatment option.